SCHEMBL5070880

SCHEMBL5070880

CC(C)(C)Cn1ccc2cc(C(=O)O)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 2/20 0.48
RAPGEF4 Q8WZA2 1/20 0.45
PPARG P37231 1/20 0.44
GRM2 Q14416 1/20 0.44
TUBB4A P04350 2/20 0.43
TUBB P07437 2/20 0.43
TUBA3C P0DPH7 2/20 0.43
TUBA1B P68363 2/20 0.43
TUBA4A P68366 2/20 0.43
TUBB4B P68371 2/20 0.43
TUBB3 Q13509 2/20 0.43
TUBB2A Q13885 2/20 0.43
TUBB8 Q3ZCM7 2/20 0.43
TUBA3E Q6PEY2 2/20 0.43
TUBA1A Q71U36 2/20 0.43
TUBA1C Q9BQE3 2/20 0.43
TUBB6 Q9BUF5 2/20 0.43
TUBB2B Q9BVA1 2/20 0.43
TUBB1 Q9H4B7 2/20 0.43
HDAC11 Q96DB2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7920896 0.85 PLA2G4A (0.46) PLA2G4ARAPGEF4PPARGTUBB4ATUBB
SCHEMBL9032672 0.84 NR4A1 (0.40) PPARG
SCHEMBL9032659 0.84 NR4A1 (0.40) PPARG
SCHEMBL5387474 0.83 TUBB4A (0.59) PLA2G4ARAPGEF4PPARGTUBB4ATUBB
SCHEMBL5068315 0.81 TUBB4A (0.57) PLA2G4ARAPGEF4PPARGTUBB4ATUBB
SCHEMBL27718498 0.80 PLG (0.48) PLA2G4ARAPGEF4PPARGTUBB4ATUBB
SCHEMBL15921713 0.80 PLA2G4A (0.55) PLA2G4ARAPGEF4PPARGTUBB4ATUBB
SCHEMBL4934703 0.80 PLA2G4A (0.55) PLA2G4ARAPGEF4TUBB4ATUBBTUBA3C
SCHEMBL28607801 0.80 KMT2A (0.60) PLA2G4ARAPGEF4PPARGTUBB4ATUBB
SCHEMBL2983210 0.80 PLA2G4A (0.48) PLA2G4ARAPGEF4PPARGTUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595866-B1 Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome SANWA KAGAKU KENKYUSHO CO (JP) 2016-06-08 EP disclosed
US-7345180-B2 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2008-03-18 US disclosed
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2006-10-12 US disclosed
EP-1595866-A1 COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV Sanwa Kagaku Kenkyusho Co., Ltd. (JP) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV DPP4, DPP3, DPP7 PLA2G4A 4463/4885RAPGEF4 4829/4885PPARG 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.